The Current Ratio as of November 2024 (TTM) for Olema Pharmaceuticals, Inc. (OLMA) is 7.10

According to Olema Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 7.10. This represents a change of -25.58% compared to the average of 9.54 of the last 4 quarters.

Olema Pharmaceuticals, Inc. (OLMA) Historical Current Ratio (quarterly & annually)

How has OLMA Current Ratio performed in the past?

The mean historical Current Ratio of Olema Pharmaceuticals, Inc. over the last ten years is 24.60. The current 7.10 Current Ratio has changed 2.79% with respect to the historical average. Over the past ten years (40 quarters), OLMA's Current Ratio was at its highest in in the December 2020 quarter at 74.62. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Olema Pharmaceuticals, Inc. (OLMA) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Olema Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Olema Pharmaceuticals, Inc. (OLMA) Average Current Ratio

How has OLMA Current Ratio performed in the past?

The current Current Ratio of Olema Pharmaceuticals, Inc. (OLMA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Olema Pharmaceuticals, Inc. (OLMA) Current Ratio vs. Peers

How is OLMA’s Current Ratio compared to its peers?

Olema Pharmaceuticals, Inc.’s Current Ratio is greater than Sana Biotechnology, Inc. (4.47), less than Cullinan Oncology, Inc. (24.46), greater than aTyr Pharma, Inc. (6.07), less than Zentalis Pharmaceuticals, Inc. (7.29), less than Molecular Partners AG (14.33), less than Mineralys Therapeutics, Inc. (8.55), less than AN2 Therapeutics, Inc. (9.75), less than Pharvaris N.V. (19.08), less than PepGen Inc. (8.47), less than Gracell Biotechnologies Inc. (7.73), less than Theseus Pharmaceuticals, Inc. (29.93), greater than Monte Rosa Therapeutics, Inc. (6.03), less than Design Therapeutics, Inc. (34.61), less than Erasca, Inc. (11.00), less than Disc Medicine, Inc. (19.36), less than Larimar Therapeutics, Inc. (13.10), less than Fennec Pharmaceuticals Inc. (7.80), greater than Orchestra BioMed Holdings, Inc. (4.23), greater than Nuvectis Pharma, Inc. (2.74), less than Centessa Pharmaceuticals plc (21.52),

Build a custom stock screener for Olema Pharmaceuticals, Inc. (OLMA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Olema Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Olema Pharmaceuticals, Inc. (OLMA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Olema Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.